ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0107103 | A member of the nerve growth factor family of trophic factors. In the brain BDNF has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. (From Kendrew, The Encyclopedia of Molecular Biology, 1994) | BDNF|brain derived neurotrophic factor|Brain-Derived Neurotrophic Factor|brain derived neurotrophic factor (BDNF)|Brain Derived Neurotrophic Factor|bdnf|Neurotrophic Factor, Brain-Derived|Factor, Brain-Derived Neurotrophic | brain-derived neurotrophic factor |
C0394477 | Application of electric current to the spine for treatment of a variety of conditions involving innervation from the spinal cord. | Spinal Cord Stimulation|spinal cord stimulation|cord spinal stimulation|Neurostimulation of spinal cord tissue|Cord Stimulation, Spinal|Stimulation, Spinal Cord|Spinal cord stimulation|SCS - Spinal cord stimulation|stimulation spinal cord|Neurostimulation of spinal cord tissue (procedure)|SCS | Neurostimulation procedures of spinal cord tissue |
C0262593 | Injuries to the PERIPHERAL NERVES. | injury nerve peripheral|peripheral nerve injury|PNI - Peripheral nerve injury|Peripheral nerve injury, NOS|peripheral nerve injuries|Injury of peripheral nerve (disorder)|Nerve Injuries, Peripheral|Nerve Injury, Peripheral|Peripheral Nerve Injury|Peripheral nerve injury|Injury of peripheral nerve|PERIPHERAL NERVE INJURY | Peripheral Nerve Injuries |
C0442874 | A nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Neuropathy may be caused by physical injury, infection, toxic substances, disease (such as cancer, diabetes, kidney failure, or malnutrition), or drugs, including anticancer drugs. | Neuropathy, NOS|NEUROPATHY|neuropathies|Neuropathy (disorder)|Neuropathy|Neuropathy (nerve damage)|neuropathy|disorders neuropathy|NEUROPATHY - (NOS) | Neuropathy |
C0687080 | The foot of a quadruped animal, including canines, felines, mice, rats, and bears. The paw contains claws or nails and pads composed of a thick keratinized dermis covering collagenous adipose tissue. | Paw|paws|Pes|Animal foot, NOS|Paw, NOS|paw|PAW|Pedal|Animal foot|Paw (body structure) | Paw |
C1427291 | null | RNF121|ring finger protein 121|RNF121 gene|FLJ11099 | RNF121 gene |
C1427291 | null | RNF121|ring finger protein 121|RNF121 gene|FLJ11099 | RNF121 gene |
C0017789 | Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. | glutamate|glutamates|Glutamates | Glutamates |
C0085845 | one of the non-essential amino acids commonly occurring in the L-form; may be a neurotransmitter. | L-Aspartate|asp|Asp|Aspartate (substance)|l-aspartate|aspartate|aspartate (Asp)|L Aspartate|Aspartate | aspartate |
C0043012 | A state in which there is an enhanced potential for sensitivity and an efficient responsiveness to external stimuli. | WAKEFULNESS|aroused|arousing|Wakefulness|Vigilance|vigilant|Wakefulness (observable entity)|Vigilant|vigilance|Wakefulnesses|Aroused|Watchfulness|wakefulness | Wakefulness |
C0175313 | null | Medial preoptic nucleus|Area praeoptica medialis|Medial preoptic area|Nucleus preopticus medialis|medial preoptic nucleus|Area, Medial Preoptic|Structure of medial preoptic nucleus (body structure)|Medial Preoptic Area|Preoptic Areas, Medial|Area preopticus medialis|Structure of medial preoptic nucleus|Areas, Medial Preoptic|Medial preoptic hypothalamic nucleus|Preoptic Area, Medial|Medial Preoptic Areas | Structure of medial preoptic nucleus |
C0007765 | The part of brain that lies behind the BRAIN STEM in the posterior base of skull (CRANIAL FOSSA, POSTERIOR). It is also known as the "little brain" with convolutions similar to those of CEREBRAL CORTEX, inner white matter, and deep cerebellar nuclei. Its function is to coordinate voluntary movements, maintain balance, and learn motor skills. | Corpus Cerebellus|Epencephalon-1|cerebellum|Cerebelli, Corpus|BRAIN, CEREBELLUM|Cerebellar structure (body structure)|Cerebellar structure|Parencephalon|CEREBELLUM|Cerebellums|Cerebellum, NOS|Corpus Cerebelli|Parencephalons|Cerebello-|Cerebellus, Corpus|CEREBELLUM, PEDUNCLES AND MEDULLA|Cerebellum|Cerebellar | Cerebellum |
C0443340 | null | Unipolar (qualifier value)|unipolar | Unipolar |
C0012881 | A non-template-directed DNA polymerase normally found in vertebrate thymus and bone marrow. It catalyzes the elongation of oligo- or polydeoxynucleotide chains and is widely used as a tool in the differential diagnosis of acute leukemias in man. EC 2.7.7.31. | Deoxyribonucleotidyltransferase, Terminal|Deoxynucleotidyl Transferase|Terminal deoxynucleotidyltransferase|Terminal Deoxyribonucleotidyl Transferase|Terminal Addition Enzyme|Deoxyribonucleic acid nucleotidylexotransferase|Nucleotidylexotransferase, DNA|Terminal addition enzyme|Terminal deoxyribonucleotidyltransferase|DNA nucleotidylexotransferase|DNA Nucleotidylexotransferase|Transferase, Deoxynucleotidyl|Enzyme, Terminal Addition|Transferase, Terminal Deoxyribonucleotidyl|Transferase, Terminal Deoxynucleotidyl|Nucleoside-triphosphate:DNA deoxynucleotidylexotransferase|Terminal Deoxynucleotidyl Transferase|Deoxyribonucleotidyl Transferase, Terminal|Deoxynucleotidyl Transferase, Terminal|Addition Enzyme, Terminal|Deoxynucleotidyltransferase|Deoxyribonucleic acid nucleotidylexotransferase (substance)|Desoxynucleotidyl Transferase|Transferase, Desoxynucleotidyl|Terminal Deoxyribonucleotidyltransferase|Desoxynucleotidyltransferase | DNA Nucleotidylexotransferase |
C0033634 | An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. | Calcium Phospholipid-Dependent Protein Kinase|Protein kinase C (substance)|Calcium Phospholipid Dependent Protein Kinase|protein kinase C (PKC)|Serine-Threonine Kinase, PKC|Calcium Activated Phospholipid Dependent Kinase|Calcium phospholipid protein kinase|protein kinase c|Protein kinase C|PKC|Calcium-Activated Phospholipid-Dependent Kinase|Phospholipid Sensitive Calcium Dependent Protein Kinase|protein kinase C|Protein Kinase C|PKC Serine-Threonine Kinase|EC 2.7.11.13|pkc|Phospholipid-Sensitive Calcium-Dependent Protein Kinase|PKC Serine Threonine Kinase|Phospholipid-Dependent Kinase, Calcium-Activated | Protein Kinase C |
C0017302 | Agents that induce various degrees of analgesia; depression of consciousness, circulation, and respiration; relaxation of skeletal muscle; reduction of reflex activity; and amnesia. There are two types of general anesthetics, inhalation and intravenous. With either type, the arterial concentration of drug required to induce anesthesia varies with the condition of the patient, the desired depth of anesthesia, and the concomitant use of other drugs. (From AMA Drug Evaluations Annual, 1994, p.173) | General Anesthetics|general anaesthetic|General anaesthetic|General anesthetic agents|anesthetics general|general anesthetics|General anaesthetic, NOS|GENERAL ANESTHETICS|General anesthetic|General anesthetic, NOS|anaesthetics general|general anesthetic|General anesthetic (substance)|Anesthetics, General|anesthetic general|ANESTHETICS, GENERAL|General anaesthetic agents|anaesthetic general | General anesthetic drugs |
C0054537 | null | Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester | calphostin C |
C0054537 | null | Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester | calphostin C |
C0070750 | null | phorbol | Phorbol |
C0011581 | An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. | depression nos|Depressivity|Depressive disorder NOS|Mood disorder of depressed type|Neurosis, depressive|Depression|Depressive Neurosis|Neuroses, Depressive|DEPRESSIVE DISORDERS|DEPRESSIVE NEUROSIS|Depressive Disorders|Depressive disorder|Depressive disorder, NOS|Depressive Disorder|depressive neurosis|Disorder, Depressive|depressive disorder|Depressive illness|depression|Depressive Neuroses|Depressive disorder (disorder)|Depressive neurosis|Neurosis, Depressive|depressive illness|Disorders, Depressive|Depressive disorders | Depressive disorder |
C0380600 | null | 1,2,3,4-tetrahydronaphthalene | tetralin |
C0004400 | The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed) | Radioautography|Autoradiography|radioautography|autoradiography | Autoradiography |
C0019564 | A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain. | Hippocampal structure|Hippocampus (Brain)|BRAIN, HIPPOCAMPUS|Hippocampus|HIPPOCAMPUS|Hippocampal structure (body structure)|Hippocampal | Hippocampus (Brain) |
C0027934 | Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. | neurotoxin|Neurotoxin (substance)|neurotoxins|Neurotoxin|Neurotoxins | Neurotoxins |
C0035975 | An inorganic dye used in microscopy for differential staining and as a diagnostic reagent. In research this compound is used to study changes in cytoplasmic concentrations of calcium. Ruthenium red inhibits calcium transport through membrane channels. | Oxychloride, Ammoniated Ruthenium|Ruthenium red|Ruthenium Oxychloride, Ammoniated|Ammoniated Ruthenium Oxychloride|Red, Ruthenium | Ruthenium Red |
C0243459 | Substances that inhibit the action of Protein Kinase A, causing disruption of a protein phosphorylation cascade in certain signal transduction pathways. | Protein Kinase A Inhibitor | PKA inhibitor |
C0012131 | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite. | Adenosine, 2',3'-dideoxy-|ddA|DIDEOXYADENOSINE|dideoxyadenosine|2',3' Dideoxyadenosine|ddA (Antiviral)|6-Amino-9-(2''3'-dideoxy-beta-D-glycero-pentofuranosyl)purine|2',3'-Dideoxyadenosine|Dideoxyadenosine | 2',3'-Dideoxyadenosine |
C0037080 | null | pathways signaling|Pathway, Signal|Pathways, Signal|pathway signaling|Signal Pathway|signal pathway | Signal Pathways |
C0086376 | Regulatory proteins that act as molecular switches. They control a wide range of biological processes including: receptor signaling, intracellular signal transduction pathways, and protein synthesis. Their activity is regulated by factors that control their ability to bind to and hydrolyze GTP to GDP. EC 3.6.1.-. | Protein, GTP-Regulatory|GTP Binding Proteins|guanine-nucleotide-regulatory protein|GTP-binding protein|G Protein|GTP-Regulatory Proteins|Guanine Nucleotide Coupling Protein|G protein (substance)|G proteins|Guanine Nucleotide Binding Protein|GTP binding protein|Proteins, GTP-Binding|GTP Regulatory Proteins|G-Proteins|GTP Regulatory Protein|Guanine Nucleotide Regulatory Proteins|g-proteins|GTP-Binding Proteins|proteins g|g-protein|Proteins, GTP-Regulatory|g proteins|G Proteins|GTP Binding Protein|Guanyl nucleotide binding protein|G protein|g protein|Protein, GTP-Binding|G-protein|G-Protein|GTP-Regulatory Protein|GTP-Binding Protein | GTP-Binding Proteins |
C0063482 | null | indolactam-V|3H-Pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-, (2S-(2R*,5R*))- | indolactam V |
C0079883 | An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA). | D-Aspartic acid, N-methyl-|N-Methylaspartate|N Methyl D aspartate|N-Methyl-D-aspartic Acid|N Methyl D aspartic Acid|n-methylaspartate (NMA)|n-methyl-d-aspartate|N Methylaspartate|N methyl D aspartate|NMDA|N-Methyl-D-aspartate|Acid, N-Methyl-D-aspartic|NMDA (N methyl D aspartate) | N-Methylaspartate |
C0205812 | potent excitatory amino acid agonist and neurotoxin from the seaweed Diginea simplex. | kainate | Kainate |
C0242704 | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. | Drugs, Histamine|Agents, Histaminergic|Drugs, Histaminergic|Histamine Drugs|Agents, Histamine|Histaminergic Drugs|Histaminergic Agents | Histamine Agents |
C0019588 | An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | HISTAMINE|histamine|beta-aminoethylglyoxaline|Histamine-containing product|Product containing histamine (medicinal product)|Histamine (substance)|2-(4-imidazolyl)ethylamine|5-Imidazoleethylamine|4-(2-Aminoethyl)-1H-imidazole|5-imidazoleethylamine|2-(4-Imidazolyl)ethylamine|Histamine|histamines|1H-Imidazole-4-ethanamine|beta-aminoethylimidazole|4-imidazoleethylamine | histamine |
C0225957 | A fibrous membrane that attaches to, and provides support for, the aortic valve leaflets. | Anulus fibrosus of aorta|AORTIC VALVE ANNULUS|Aortic valve ring|Anulus of aortic valve|Fibrous ring of aortic valve|Structure of anulus fibrosus of aorta|Aortic Valve Annulus|Aortic anulus|Structure of anulus fibrosus of aorta (body structure)|Aortic valvar anulus|Aortic valve anulus|Aortic ring | Structure of anulus fibrosus of aorta |
C0684074 | null | rams | rams |
C0010096 | The lysis or structural demise of the corpus luteum. During normal luteolysis, two closely related events occur. First, there is loss of the capacity to synthesize and secrete progesterone (functional luteolysis) followed by loss of the cells that comprise the corpus luteum (structural luteolysis). Preventing luteolysis is crucial to maintain pregnancy. [http://ovary.stanford.edu, PMID:10617764] | Regression, Corpus Luteum|luteolysis|Corpus Luteum Regression|Luteal Regression|Regression, Luteal | Luteolysis |
C0376448 | A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation. | Cells, Jurkat|Jurkat Cell|jurkat cells|Cell, Jurkat|Jurkat cell | Jurkat Cells |
C1159825 | Caspase Activation involves induction of the activity of intracellular cysteine endopeptidase family members kept inactive by mitochondrial surface proteins (BcL-2 Family) and involved in initial signaling and downstream proteolytic cleavages (at P1 aspartic acids) in inflammation and apoptotic cell death when signals block BcL-2 function and activators initiate caspase cascades. | activation of caspase activity|activation of cysteine-type endopeptidase activity involved in apoptotic process|caspase activation | Caspase Activation |
C0001302 | Designated locations along nerves or organ meridians for inserting acupuncture needles. | points acupuncture|Acupuncture points|Points, Acupuncture|Acupoint|acupoints|acupuncture points|Acupoints|acupoint|Point, Acupuncture|acupuncture point|Acupuncture point (body structure)|Acupuncture point|Acupuncture Point | Acupuncture Points |
C0001302 | Designated locations along nerves or organ meridians for inserting acupuncture needles. | points acupuncture|Acupuncture points|Points, Acupuncture|Acupoint|acupoints|acupuncture points|Acupoints|acupoint|Point, Acupuncture|acupuncture point|Acupuncture point (body structure)|Acupuncture point|Acupuncture Point | Acupuncture Points |
C0348070 | The 32 teeth of adulthood that either replace or are added to the complement of deciduous teeth. (Boucher's Clinical Dental Terminology, 4th ed) | Dentes permanentes|dentition permanent|Adult Dentition|Adult dentition|Dentition, Permanent|Secondary Dentition|Permanent dentition|All permanent teeth, NOS|permanent tooth|Permanent tooth|Dentition, Adult|Permanent teeth|Secondary dentition|Permanent tooth, NOS|Permanent Tooth|permanent teeth|Structure of permanent tooth (body structure)|Structure of permanent tooth|Dentition, Secondary|Set of secondary teeth|PERMANENT TEETH|Set of permanent teeth|All permanent teeth (body structure)|teeth permanent|Secondary tooth|Permanent Teeth|All permanent teeth|Permanent Dentition | Structure of permanent tooth |
C0066005 | A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. | (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid|Meropenem|Meropenem (substance)|Meropenemum|MEROPENEM|meropenem|1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-|3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid|Product containing meropenem (medicinal product)|Meropenem-containing product | meropenem |
C1568490 | A dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Muraglitazar causes an increase in HDL-C levels, and a decrease in total cholesterol, apolipoprotein B, triglycerides and HbA1c. This agent is associated with an increased risk of adverse cardiovascular events and heart failure. | N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine|MURAGLITAZAR|2-((4-methoxyphenoxy)carbonyl-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid|Muraglitazar | muraglitazar |
C0599748 | A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. | Mass Spectrometry Mass Spectrometry|MS/MS|Mass Spectrometry-Mass Spectrometry|Mass Spectrometry, Tandem|mass spectrometry tandem|Tandem mass spectrometry|MS2|Tandem Mass Spectrometry|tandem mass spectrometry | Tandem Mass Spectrometry |
C0034809 | Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example. | Glucocorticoid Receptor|Glucocorticoid receptor (substance)|glucocorticoid receptors|Receptor, Glucocorticoid|Glucocorticoid Receptors|Glucocorticoids--Receptors|Glucocorticoid receptor|Glucocorticoids Receptors|Glucocorticoid receptor site|Receptors, Glucocorticoid|Receptors, Glucocorticoids|glucocorticoid receptor | Glucocorticoid Receptor |
C0872189 | null | Huntington gene | huntington gene |
C0054594 | A class of G-protein-coupled receptors that are specific for CANNABINOIDS such as those derived from CANNABIS. They also bind a structurally distinct class of endogenous factors referred to as ENDOCANNABINOIDS. The receptor class may play a role in modulating the release of signaling molecules such as NEUROTRANSMITTERS and CYTOKINES. | Cannabinoid Receptors|cannabinoid receptor|Receptors, Cannabinoid|Receptor, Cannabinoid|receptor cannabinoid|cannabinoid receptors|Cannabinoid Receptor | cannabinoid receptor |
C0075111 | null | 4-Pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl-|SR-95191 | SR 95191 |
C0075111 | null | 4-Pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl-|SR-95191 | SR 95191 |
C0392348 | null | ideation|Ideation, function (observable entity)|Ideation, NOS|Ideation, function | Ideation |
C0011253 | A false belief regarding the self or persons or objects outside the self that persists despite the facts, and is not considered tenable by one's associates. | Delusional ideas|DELUSION|Delusion|Delusional thoughts|Delusions|Delusions (finding)|delusion|DELUSIONS|delusions|Delusion, NOS | Delusions |
C0018524 | Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS. | hallucinations|Hallucination|hallucinating|HALLUCINATIONS|Hallucination, NOS|hallucinated|hallucinate|Hallucinations|hallucination|Hallucinations (finding)|HALLUCINATION|Hallucinations NOS | Hallucinations |
C0338656 | Interference or disruption of cognitive processes. This term encompasses a large number of problems and issues associated with intellectual functioning and information processing. 2005 | Cognitive deficits|Cognitive Impairments|Cognitive defects|cognitive dysfunction|Cognitive impairment|Dysfunction, Cognitive|Cognitive decline|Cognitive deficit|Impairments, Cognitive|Cognitive Disturbance|Cognitive Impairment|Dysfunctions, Cognitive|Neurocognitive Dysfunction|Cognitive Dysfunction|Impairment, Cognitive|Impaired cognition (finding)|cognitive impairment|impaired cognition|Cognitive dysfunction|Impaired cognition|Disturbance in cognition|COGNITIVE DISTURBANCE|cognitive decline|cognitive dysfunctions|cognitive impairments|Cognitive disturbance|Cognitive Dysfunctions|Neurocognitive Disturbance | Impaired cognition |
C0036825 | Dissolved proteins of blood plasma. These mainly consist of albumins and globulins and include antibodies and blood-clotting proteins. | serum proteins|protein serum|Serum protein (substance)|Serum Proteins|Serum protein|Proteins, Serum|Protein, serum|Serum Protein|Serum protein, NOS|serum protein|Plasma Protein|proteins serum | Serum Proteins |
C0225698 | Epithelial cells that line the PULMONARY ALVEOLI. | Alveolar Cell|Alveolar Epithelial Cell|Cells, Alveolar Epithelial|Alveolar cell|Alveolar Cells|Pneumocytes|Cell, Alveolar|Pneumonocyte|pneumocytes|alveolar cells epithelial|Pneumocyte (cell)|Pneumocyte, NOS|Cell, Alveolar Epithelial|pneumocyte|Cells, Alveolar|Epithelial Cells, Alveolar|Epithelial Cell, Alveolar|Pneumocyte|Alveolar epithelial cell | Alveolar Epithelial Cells |
C0048504 | A pyrazole with competitive alcohol dehydrogenase inhibitor activity. Fomepizole prevents the metabolism of ethylene glycol and methanol by alcohol dehydrogenase, thereby inhibiting the formation of their toxic metabolites, glycolate and oxalate (from ethylene glycol), and formic acid (from methanol). Fomepizole is indicated for use as an antidote in ethylene glycol and methanol poisoning. (NCI05) | 4-methylpyrazole|Fomepizolum|4-Methylpyrazole|Product containing fomepizole (medicinal product)|Fomepizole-containing product|fomepizole|4-Methylpyrazol|Fomepizole (substance)|FOMEPIZOLE|4-methylpyrazol|4 Methylpyrazole|Fomepizol|1H-Pyrazole, 4-methyl-|Fomepizole | fomepizole |
C0392621 | condition or physical state produced by the ingestion, injection or inhalation of, or exposure to methanol. | Methanol poisoning|methanol poisoning|METHYL ALCOHOL POISONING|Methyl alcohol poisoning|Methyl alcohol poisoning syndrome|methyl alcohol poisoning | Methyl alcohol poisoning |
C0001963 | A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness. | Methyl Alcohol|carbinol|Methyl alcohol|Wood naphtha|Alcohol, Methyl|methanol|METHYL ALCOHOL|wood alcohol|alcohol wood|methyl alcohol|Carbinol|METHANOL|ALCOHOL,METHYL|Alcohol, Wood|Wood alcohol|Wood Alcohol|Methanol (substance)|Methanol | methanol |
C0173095 | null | 2,6-Piperazinedione, 4-methyl-|4-methyl-2,6-piperazinedione|4-MP | 4-methylpiperazine-2,6-dione |
C0001963 | A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness. | Methyl Alcohol|carbinol|Methyl alcohol|Wood naphtha|Alcohol, Methyl|methanol|METHYL ALCOHOL|wood alcohol|alcohol wood|methyl alcohol|Carbinol|METHANOL|ALCOHOL,METHYL|Alcohol, Wood|Wood alcohol|Wood Alcohol|Methanol (substance)|Methanol | methanol |
C0701491 | null | Faslodex|faslodex|Faslodex(ICI 182,780) | Faslodex |
C0935916 | An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer. | (7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol|7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol|Fulvestrant-containing product|Fulvestrant|Fulvestrant (substance)|Product containing fulvestrant (medicinal product)|fulvestrant|7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol|FULVESTRANT | fulvestrant |
C0853879 | A carcinoma that infiltrates the breast parenchyma. The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU). Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ. It is the most common carcinoma affecting women. | Invasive breast carcinoma|Invasive Mammary Carcinoma|Invasive carcinoma of breast (disorder)|Infiltrating Breast Carcinoma|Infiltrating Carcinoma of the Breast|infiltrating breast cancer|breast cancer invasive|invasive breast cancer|Invasive Breast Cancer|Invasive Breast Carcinoma|Infiltrating Carcinoma of Breast|Invasive Carcinoma of Breast|Invasive Carcinoma of the Breast | Invasive carcinoma of breast |
C0033308 | The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. | Progesterone-containing product|Progesterona|Progesteronum|Corpus Luteum Hormone|Therapeutic Progesterone|progesterones|Delta4-pregnene-3,20-dione|17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione|PROGESTERONE|PRG - Progesterone|Lutogynon|delta4-pregnene-3,20-dione|Gelbkörperhormon|delta(4)-Pregnene-3,20-dione|Pregnenedione|Pregnendione preparation|Product containing progesterone (medicinal product)|17alpha-Progesterone|luteal hormone|Progesteron|PRG|Progesterone (substance)|progesterone|(S)-Progesterone|Progestérone|Progesterone|(S)-4-Pregnene-3,20-dione|Progesterone preparation|17α-progesterone|(S)-Pregn-4-en-3,20-dione|Pregn-4-ene-3,20-dione|Corpus luteum hormone|therapeutic progesterone | progesterone |
C0683468 | null | invasive treatments|treatment invasive|invasive treatment | invasive treatment |
C0013089 | Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. | DOXOrubicin|(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione|Doxorubicin (substance)|5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-|(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione|Product containing doxorubicin (medicinal product)|doxorubicin|14-Hydroxydaunomycin|Doxorubicinum|Hydroxyldaunorubicin|Doxorubicin-containing product|adr|14-hydroxydaunomycin|Hydroxyl Daunorubicin|Doxorubicin|Doxorubicine|(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside|ADM|(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione|ADR|Doxorubicina|14-hydroxydaunorubicine|DOXORUBICIN|DOX | doxorubicin |
C0020823 | Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. | Ifosfamidum|Isophosphamide|Ifosfamide (substance)|Ifosfamide-containing product|isophosphamide|ipps|IFO|3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide|Iphosphamide|Isoendoxan|Isofosfamide|IFX|3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide|Naxamide|Iso-Endoxan|Product containing ifosfamide (medicinal product)|Iso Endoxan|iphosphamide|ipp|Ifosfamide|IFOSFAMIDE|Ifosfamida|Iphosphamid|isofosfamide|2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide|Isosfamide|IPP|IFF|2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin- 2-amine|N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide|ifosfamide | ifosfamide |
C1261473 | A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. | Sarcoma, Soft Tissue|Sarcomas, Soft Tissue|Soft tissue tumour, malignant|Cancer of connective tissue|Sarcomas|Sarcoma, no ICD-O subtype|Soft Tissue Sarcoma|Sarcoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant connective tissue tumor|Sarcoma, no International Classification of Diseases for Oncology subtype|Malignant mesenchymal tumor|sarcoma|Mesenchymal tumour, malignant|Mesenchymal tumor, malignant|Soft tissue sarcoma|Malignant mesenchymal tumour|SARCOMA|Soft tissue tumor, malignant|Sarcoma, NOS|Sarcoma of Soft Tissue and Bone|Sarcoma|Mesenchymal Tumor, Malignant|Soft Tissue Sarcomas|SARCOMA, MALIGNANT|Sarcoma (disorder)|Sarcoma of the Soft Tissue and Bone | Sarcoma |
C1516334 | The cell cycle is an ordered set of events. Progression through the stages of cell cycle, including G1-S-G2-M, culminates in cell growth and division into two daughter cells. | null | Cell Cycle Progression |
C0282491 | The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells. | Lymph node germinal center|Germinal Center|Centers, Germinal|Secondary lymphoid nodule|germinal center|Germinal centre of lymph node|Germinal center|Peripheral lymphoid tissue|Center, Germinal|Lymph Node Germinal Center|Structure of germinal centre of lymph node|Germinal center of lymph node|Structure of germinal center of lymph node|Structure of germinal center of lymph node (body structure)|Germinal Centers|Secondary nodular lymphoid tissue|germinal centers|centers germinal|Secondary lymphoid tissue | Structure of germinal center of lymph node |
C0167627 | A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1. | Lymphocyte antigen CD154 (substance)|Lymphocyte antigen CD154|TRAP ligand|cd40 ligand|rhu CD40L|gp39 Antigen, T-Cell|CD40 ligand|T-Cell gp39 Antigen|Antigens, CD154|CD40 Ligand|CD40LG|CD154 antigen|gp39|cd40l|cd154|T-BAM|Tumor Necrosis Factor Ligand Superfamily Member 5|TNF Superfamily, Member 5|Antigen, CD154|gp39 Antigen, T Cell|CD40-ligand|TNF-related activation protein|CD40L|CD154 Antigens|T-cell antigen gp39|T-B Cell Activating Molecule|CD154 Antigen | CD40 Ligand |
C0242245 | Non-hematopoietic cells, with extensive dendritic processes, found in the primary and secondary follicles of lymphoid tissue (the B cell zones). They are different from conventional DENDRITIC CELLS associated with T-CELLS. They are derived from MESENCHYMAL STEM CELLS and are negative for class II MHC antigen and do not process or present antigen like the conventional dendritic cells do. Instead, follicular dendritic cells have FC RECEPTORS and C3B RECEPTORS that hold antigen in the form of ANTIGEN-ANTIBODY COMPLEXES on their surfaces for long periods for recognition by B-CELLS. | follicular dendritic cell|follicular dendritic cells|Follicular dendritic cell|Follicular dendritic cell (cell)|Follicular Dendritic Cells|Dendritic Reticulum Cells, Follicular|Follicular Dendritic Cell|Dendritic Cell, Follicular|Dendritic reticulum cell|Reticulum cell, dendritic | Dendritic Cells, Follicular |
C0600508 | Nucleotide sequences, usually upstream, which are recognized by specific regulatory transcription factors, thereby causing gene response to various regulatory agents. These elements may be found in both promoter and enhancer regions. | Response Element|Elements, Response|Element, Response|Response Elements | Response Elements |
C0003609 | A geographical area of the United States with no definite boundaries but comprising northeastern Alabama, northwestern Georgia, northwestern South Carolina, western North Carolina, eastern Kentucky, eastern Tennessee, western Virginia, West Virginia, western Maryland, southwestern Pennsylvania, southern Ohio, and southern New York. | Appalachia|appalachia|Appalachian Region | Appalachian Region |
C0033930 | The science dealing with the correlation of the physical characteristics of a stimulus, e.g., frequency or intensity, with the response to the stimulus, in order to assess the psychologic factors involved in the relationship. | Psychophysics|Psychophysic|psychophysics | Psychophysics |
C0033930 | The science dealing with the correlation of the physical characteristics of a stimulus, e.g., frequency or intensity, with the response to the stimulus, in order to assess the psychologic factors involved in the relationship. | Psychophysics|Psychophysic|psychophysics | Psychophysics |
C0312586 | A heterogeneous antibody derived from a host organism, typically produced by immunization of a suitable mammal with an antigen which induces B-lymphocytes to produce IgG immunoglobulins specific for the antigen. The resulting collection of antibodies have specificity for different epitopes of the antigen. | Polyclonal antibody|antibodies polyclonal|Polyclonal antibody (substance)|polyclonal antibody|Polyclonal Antibody | Polyclonal antibody |
C0024727 | Polysaccharides consisting of mannose units. | mannan|mannans|Mannan | Mannans |
C0048451 | null | D,L-p-methoxyamphetamine|4-methoxyamphetamine|P-methoxyamphetamine|P-methoxyamfetamine|para-methoxyamphetamine|(2RS)-1-(4-methoxyphenyl)propan-2-amine|p-methoxy-alpha-methylphenethylamine|pma|paramethoxyamphetamine|para-methoxyamphetamine (PMA)|Formoterol fumarate related compound G|4-methoxyamfetamine|4-methoxyamphetamine (substance)|p-methoxyamphetamine|Paramethoxyamphetamine|Para-methoxyamphetamine|PMA|4-Methoxyamphetamine | 4-methoxyamphetamine |
C0019000 | Any blood or formed element especially in invertebrates. | hemocytes|Hemocyte|Hemocytes|hemocyte|Hematocyte | Hemocytes (cell) |
C0020281 | A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. | Product containing hydrogen peroxide (medicinal product)|Hydrogen dioxide|Hydrogen Peroxide|hydrogen peroxide|Hydrogen Dioxide|Hydrogen peroxide (substance)|Hydrogen Peroxide (H2O2)|HOOH|Hydrogen peroxide|HYDROGEN PEROXIDE|Hydroperoxide|Hydrogen peroxide (H2O2)|Hydrogen peroxide-containing product|H2O2|Dihydrogen Dioxide|Peroxide, Hydrogen|Dihydrogen Peroxide | hydrogen peroxide |
C0245355 | PROTEINS that specifically activate the GTP-phosphohydrolase activity of RAS PROTEINS. | ras-GAPs|ras GTPase Activating Proteins|GTPase-Activating Proteins, ras|ras-GAP|ras GAPs|ras GAP | ras GTPase-Activating Proteins |
C0245355 | PROTEINS that specifically activate the GTP-phosphohydrolase activity of RAS PROTEINS. | ras-GAPs|ras GTPase Activating Proteins|GTPase-Activating Proteins, ras|ras-GAP|ras GAPs|ras GAP | ras GTPase-Activating Proteins |
C0017205 | An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement. | Glucocerebrosidoses|Histiocytoses, Kerasin|gauchers disease|Disease, Gaucher|Glucocerebrosidase Deficiency Diseases|gaucher's disease|Cerebroside Lipidoses, Glucosyl|thesaurismosis, Kerasin|Glucosyl Cerebroside Lipidoses|Glucosyl Cerebroside Lipidosis|HISTIOCYTOSIS, LIPID, KERASIN TYPE|disease gauchers|Cerebroside Lipidosis, Glucosyl|LIPIDOSIS, CEREBROSIDE|Glucocerebrosidase deficiency|Lipidoses, Glucosylceramide|ANEMIA, SPLENIC, FAMILIAL|familial splenic anemia|Lipoid Histiocytosis (Kerasin Type)|Lipidosis, Glucosylceramide|Gaucher splenomegaly|Lipidosis Syndrome, Cerebroside|Gaucher's Disease|Chronic non-neuropathic Gaucher disease|Glucosylceramide Lipidosis|GAUCHER DISEASE|Histiocytosis, Lipoid (Kerasin Type)|Histiocytosis, Kerasin|Kerasin histiocytosis|disease gaucher|Lipoidosis, Kerasin|Glucosylceramide Beta-Glucosidase Deficiency|Glucosylceramide Beta-Glucosidase Deficiency Disease|Glucocerebrosidase Deficiency Disease|Gaucher disease|Disease, Glucocerebrosidase Deficiency|Glucosylceramidase deficiency|Kerasin thesaurismosis (disorder)|lipoid histiocytosis (kerasin type)|Gaucher's disease, NOS|Acid beta-Glucosidase Deficiency Disease|Gaucher's disease|Kerasin thesaurismosis|Glucosylceramidase Deficiency|Lipidoses, Glucosyl Cerebroside|Cerebroside Lipidosis Syndromes|Lipoid Histiocytoses (Kerasin Type)|Splenomegaly, Gaucher|Diseases, Gauchers|Kerasin Lipoidoses|glucosylceramide lipidosis|Lipidosis, Glucosyl Cerebroside|Disease, Gauchers|Lipoidoses, Kerasin|Glucocerebrosidase Deficiencies|Chronic adult Gaucher's disease|Syndromes, Cerebroside Lipidosis|Kerasin lipoidosis|Glucocerebrosidase Deficiency|CEREBROSIDE LIPOIDOSIS GAUCHERS ADULT FORM|Cerebroside lipidosis syndrome|glucosylceramidase deficiency|Deficiencies, Glucocerebrosidase|gaucher disease|Deficiency, Glucocerebrosidase|Kerasin Histiocytosis|thesaurismoses, Kerasin|Kerasin Histiocytoses|Glucosylceramide Lipidoses|Chronic non-neuropathic Gaucher's disease (disorder)|disease gaucher's|Lipidosis Syndromes, Cerebroside|Deficiency Disease, Glucocerebrosidase|CEREBROSIDE LIPOIDOSIS <GAUCHERS ADULT FORM>|Glucosylceramide beta-glucosidase deficiency (disorder)|Adult Gaucher disease|Glucosylceramide beta-glucosidase deficiency|Deficiency Diseases, Glucocerebrosidase|GLUCOSYL CEREBROSIDE LIPIDOSIS|Gaucher Syndrome|Glucosylceramidase deficiency, chronic type|Histiocytoses, Lipoid (Kerasin Type)|Kerasin thesaurismoses|glucocerebrosidosis|Gaucher Disease|Syndrome, Cerebroside Lipidosis|Disease, Gaucher's|gaucher syndrome|Gaucher Splenomegaly|Cerebroside Lipidosis Syndrome|Kerasin Lipoidosis|Gauchers Disease|Gaucher syndrome|Diseases, Glucocerebrosidase Deficiency|Acid beta-Glucosidase Deficiency|Gaucher's disease, type I|Chronic non-neuropathic Gaucher's disease|Glucocerebrosidosis|Gauchers Diseases|Syndrome, Gaucher | Gaucher Disease |
C0005940 | Diseases of BONES. | Diseases, Bone|DISORDER BONE (NOS)|Bone disease|Disorder of bone|BONE DISORDER (NOS)|bone disorder|Osteopathia|bones disease|diseases of the bones|Bones--Diseases|bone disease|Bone Disorders|Disorder of bone (disorder)|OSTEOPATHY|Bone Diseases|bone disorders|bone diseases|bones disorders|the diseases of bones|Disease of bone, NOS|BONE DISORDER|Bone Disease|osteopathy|Osteopathy|bones diseases|Bone disease, NOS|disease of bone|Diseases of Bones|Disease, Bone|Disease of bone|DISEASES OF THE BONES|Osteopathia, NOS | Bone Diseases |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C0073918 | null | Saave | SAAVE |
C1306772 | The bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a muscarinic receptor antagonist, with bronchodilating activity. Although it does not display selectivity for specific muscarinic receptors, on topical application, tiotropium bromide acts mainly on M3 muscarinic receptors located on smooth muscle cells and submucosal glands, preventing smooth muscle contraction and mucus secretion, thus producing a bronchodilatory effect. | 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide|tiotropium bromide|Bromide, Tiotropium|Tiotropium bromide|Tiotropium bromide (substance)|TIOTROPIUM BROMIDE|Tiotropium Bromide | tiotropium bromide |
C0213771 | null | TIOTROPIUM|Tiotropium-containing product|tiotropium|Product containing tiotropium (medicinal product)|Tiotropium (substance)|Tiotropium | tiotropium |
C0005330 | An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. | BEZAFIBRATE|2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid|Bezafibrato|Propanoic Acid, 2-(4-(2-((4-Chlorobenzoyl)Amino)Ethyl)Phenoxy)-2-Methyl-|Bezafibrate|Bezafibrate (substance)|Product containing bezafibrate (medicinal product)|Bezafibrate-containing product|bezafibrate|2-(p-(2-(p-Chlorobenzamido)Ethyl)Phenoxy)-2-Methylpropionic Acid|Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-|Bezafibratum | bezafibrate |
C0086061 | null | beta-Cholestan-3 beta-ol, 5|beta-ol, 5 beta-Cholestan-3|Coprostanol (substance)|Coprostanol|5 beta Cholestan 3 beta ol | 5 beta-Cholestan-3 beta-ol |
C0017245 | A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. | gemfibrosil|gemfibrozil|Gemfibrozil|Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-|Gemfibrosil|2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure|Gemfibrozil-containing product|2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid|Gemfibrozilum|Gemfibrozilo|Product containing gemfibrozil (medicinal product)|Gemfibrozil (substance)|GEMFIBROZIL|2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure | gemfibrozil |
C0038710 | Antibacterial, potentially toxic, used to treat certain skin diseases. | Sulphapyridin|Sulfapyridine|N(1)-Pyridylsulfanilamide|4-[(2-Pyridylamino)sulfonyl]aniline|sulphapyridine|Sulfapiridina|Sulfapyridinum|2-(p-Aminobenzenesulphonamido)pyridine|2-Sulfapyridine|4-Amino-N,2-pyridinylbenzenesulfonamide|Sulfapyridin|2-Sulfanilamidopyridine|2-Sulfanilamidopyridin|Benzenesulfonamide, 4-amino-N-2-pyridinyl-|Solfapiridina|Sulphapyridine|sulfapyridine|4-(2-Pyridinylsulfonyl)aniline|SULFAPYRIDINE|4-Amino-N-pyridin-2-yl-benzenesulfonamide|N(1)-2-Pyridylsulfanilamide|2-Sulfanilylaminopyridine|Sulfapyridine (substance)|sulphapyridin|N-2-Pyridylsulfanilamide | sulfapyridine |
C0005330 | An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. | BEZAFIBRATE|2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid|Bezafibrato|Propanoic Acid, 2-(4-(2-((4-Chlorobenzoyl)Amino)Ethyl)Phenoxy)-2-Methyl-|Bezafibrate|Bezafibrate (substance)|Product containing bezafibrate (medicinal product)|Bezafibrate-containing product|bezafibrate|2-(p-(2-(p-Chlorobenzamido)Ethyl)Phenoxy)-2-Methylpropionic Acid|Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-|Bezafibratum | bezafibrate |
C0027396 | An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. | (S)-2-(6-Methoxy-2-naphthyl)propionic acid|(+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid|naproxen|(+)-2-(Methoxy-2-naphthyl)-propionic acid|(+)-2-(6-Methoxy-2-naphthyl)propionic acid|Naproxen (substance)|(+)-(S)-Naproxen|Naproxeno|(+)-2-(Methoxy-2-naphthyl)-propionsäure|Naproxène|d-2-(6-Methoxy-2-naphthyl)propionic Acid|Product containing naproxen (medicinal product)|(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid|(S)-(+)-Naproxen|(S)-Naproxen|(S)-2-(6-Methoxy-2-naphthyl)propanoic acid|NAPROXEN|6-Methoxy-alpha-methyl-2-naphthaleneacetic Acid|(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid|(+)-Naproxen|2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-|Naproxen-containing product|Naproxenum|Naproxen|Methoxypropiocin | naproxen |
C0028458 | An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) | Novobiocin-containing product|Novobiocine|Novobiocina|Benzamide, N-(7-((3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-beta-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-|Novobiocin (substance)|Streptonivicin|NBC|novobiocin|Crystallinic Acid|Product containing novobiocin (medicinal product)|Novobiocinum|N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide|Novobiocin|NOVOBIOCIN | novobiocin |
C0014894 | Encoded by Esterase Genes, Esterases catalyze hydrolysis of ester bonds to produce alcohol and acid reaction products. (NCI) | Ester Hydrolase|ESTERASE|EC 3.1|Esterase|Esterase (substance)|esterases|esterase|Esterases|ester hydrolase | Esterases |
C1511617 | Any environment-to-cell cummunication that involves cytokines. This process is involved in immune function. | Cytokine Signal Transduction | Cytokine Signaling |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.